Physician profile
John Mirrell Clark
NPI 1609815786
$1,107.63
in general payments reported to CMS, 2019-2025
11 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $13.42 · 2021: $461 · 2022: $255 · 2023: $80.68 · 2024: $76.35 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.59 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $189.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $147.89 | 2022-2025 | Freestyle Libre 3 |
| Alnylam Pharmaceuticals INC. | $147.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.93 | 2019-2022 | |
| Amgen INC. | $40.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $39.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.39 | 2022 | |
| Exact Sciences Corporation | $17.08 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $15.56 | 2024 | Airsupra |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.